10-Q 1 pktx_10q.htm FORM 10-Q
0001128189 false --12-31 Q3 0001128189 2023-01-01 2023-09-30 0001128189 2023-10-18 0001128189 2023-09-30 0001128189 2022-12-31 0001128189 2023-07-01 2023-09-30 0001128189 2022-07-01 2022-09-30 0001128189 2022-01-01 2022-09-30 0001128189 us-gaap:CommonStockMember 2022-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001128189 us-gaap:RetainedEarningsMember 2022-12-31 0001128189 us-gaap:CommonStockMember 2023-06-30 0001128189 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001128189 us-gaap:RetainedEarningsMember 2023-06-30 0001128189 2023-06-30 0001128189 us-gaap:CommonStockMember 2021-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001128189 us-gaap:RetainedEarningsMember 2021-12-31 0001128189 2021-12-31 0001128189 us-gaap:CommonStockMember 2022-06-30 0001128189 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001128189 us-gaap:RetainedEarningsMember 2022-06-30 0001128189 2022-06-30 0001128189 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001128189 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001128189 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001128189 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001128189 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001128189 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001128189 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001128189 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001128189 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001128189 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001128189 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001128189 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001128189 us-gaap:CommonStockMember 2023-09-30 0001128189 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001128189 us-gaap:RetainedEarningsMember 2023-09-30 0001128189 us-gaap:CommonStockMember 2022-09-30 0001128189 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001128189 us-gaap:RetainedEarningsMember 2022-09-30 0001128189 2022-09-30 0001128189 2015-01-01 2015-12-31 0001128189 2015-12-31 0001128189 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001128189 us-gaap:StockOptionMember 2022-01-01 2022-09-30 0001128189 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001128189 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001128189 us-gaap:PatentsMember 2021-12-31 0001128189 PKTX:PatentApplicationRightsMember 2021-12-31 0001128189 us-gaap:PatentsMember 2022-01-01 2022-12-31 0001128189 PKTX:PatentApplicationRightsMember 2022-01-01 2022-12-31 0001128189 2022-01-01 2022-12-31 0001128189 us-gaap:PatentsMember 2022-12-31 0001128189 PKTX:PatentApplicationRightsMember 2022-12-31 0001128189 us-gaap:PatentsMember 2023-01-01 2023-09-30 0001128189 PKTX:PatentApplicationRightsMember 2023-01-01 2023-09-30 0001128189 us-gaap:PatentsMember 2023-09-30 0001128189 PKTX:PatentApplicationRightsMember 2023-09-30 0001128189 PKTX:PatentApplicationRightsMember 2015-01-01 2015-12-31 0001128189 PKTX:PatentApplicationRightsMember 2016-01-01 2016-12-31 0001128189 srt:MinimumMember 2023-09-30 0001128189 srt:MaximumMember 2023-09-30 0001128189 us-gaap:StockOptionMember 2023-09-30 0001128189 us-gaap:StockOptionMember 2022-09-30 0001128189 us-gaap:StockOptionMember 2021-12-31 0001128189 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001128189 us-gaap:StockOptionMember 2022-12-31 0001128189 PKTX:StockOption1Member 2023-09-30 0001128189 PKTX:StockOption2Member 2023-09-30 0001128189 PKTX:StockOption3Member 2023-09-30 0001128189 us-gaap:WarrantMember 2021-12-31 0001128189 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001128189 us-gaap:WarrantMember 2022-12-31 0001128189 us-gaap:WarrantMember 2023-09-30 0001128189 PKTX:Warrant1Member 2023-09-30 0001128189 PKTX:Warrant1Member 2023-01-01 2023-09-30 0001128189 PKTX:Warrant2Member 2023-09-30 0001128189 PKTX:Warrant2Member 2023-01-01 2023-09-30 0001128189 PKTX:Warrant3Member 2023-09-30 0001128189 PKTX:Warrant3Member 2023-01-01 2023-09-30 0001128189 PKTX:Warrant4Member 2023-09-30 0001128189 PKTX:Warrant4Member 2023-01-01 2023-09-30 0001128189 PKTX:Warrant5Member 2023-09-30 0001128189 PKTX:Warrant5Member 2023-01-01 2023-09-30 0001128189 PKTX:Warrant6Member 2023-09-30 0001128189 PKTX:Warrant6Member 2023-01-01 2023-09-30 0001128189 PKTX:Warrant7Member 2023-09-30 0001128189 PKTX:Warrant7Member 2023-01-01 2023-09-30 0001128189 PKTX:Warrant8Member 2023-09-30 0001128189 PKTX:Warrant8Member 2023-01-01 2023-09-30 0001128189 PKTX:Warrant9Member 2023-09-30 0001128189 PKTX:Warrant9Member 2023-01-01 2023-09-30 0001128189 us-gaap:PrivatePlacementMember 2023-01-01 2023-09-30 0001128189 us-gaap:PrivatePlacementMember 2023-09-30 0001128189 us-gaap:PrivatePlacementMember 2022-01-01 2022-09-30 0001128189 us-gaap:PrivatePlacementMember 2022-09-30 0001128189 PKTX:PrivatePlacement1Member 2022-01-01 2022-09-30 0001128189 PKTX:PrivatePlacement1Member 2022-09-30 0001128189 PKTX:PrivatePlacement2Member 2022-01-01 2022-09-30 0001128189 PKTX:PrivatePlacement2Member 2022-09-30 0001128189 srt:ChiefFinancialOfficerMember 2023-01-01 2023-09-30 0001128189 srt:ChiefFinancialOfficerMember 2022-01-01 2022-09-30 0001128189 srt:ChiefExecutiveOfficerMember 2022-03-01 2022-03-15 0001128189 srt:DirectorMember 2022-03-01 2022-03-15 0001128189 2022-03-01 2022-03-15 0001128189 2022-03-15 0001128189 2022-12-01 2022-12-07 0001128189 srt:ChiefFinancialOfficerMember 2022-03-01 2022-03-15 0001128189 srt:ChiefFinancialOfficerMember 2022-03-15 0001128189 srt:ChiefFinancialOfficerMember 2022-12-01 2022-12-07 0001128189 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001128189 us-gaap:StockOptionMember 2022-01-01 2022-09-30 0001128189 PKTX:ConsultantMember 2017-01-01 2017-01-02 0001128189 PKTX:ConsultantMember 2019-03-30 2019-04-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2023

 

OR

  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to ___________________.

 

Commission File Number: 000-32917

 

 

PROTOKINETIX, INCORPORATED

(Exact name of registrant as specified in its charter) 

 

 

Nevada   94-3355026
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

 

 

109 W Main St.

Dalton, Ohio 44618

 
  (Address of principal executive offices, including zip code)  

 

  (Registrant’s telephone number, including area code: 740-434-5041)  

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
N/A        

 

Securities registered pursuant to Section 12(b) of the Act:

$.0000053 par value common stock

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes    No

 

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes    No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer     Accelerated filer 
Non-accelerated filer   Smaller reporting company
Emerging growth company     

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   

Yes    No  

 

As of October 18, 2023 there were 338,880,151 shares of ProtoKinetix, Incorporated common stock that were issued and outstanding.

 

 
 

 

 

 

PROTOKINETIX, INCORPORATED

TABLE OF CONTENTS

 

 

PART I  
   
FINANCIAL INFORMATION  
   
Item 1. Financial Statements 3
   
Unaudited Balance Sheets 3
   
Unaudited Statements of Operations 4
   
Unaudited Statement of Stockholders’ Equity 5
   
Unaudited Statements of Cash Flows 6
   
Notes to Unaudited Financial Statements 7
   
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 18
   
Item 3. Quantitative and Qualitative Disclosures About Market Risk 23
   
Item 4. Controls and Procedures 23
   
PART II  
   
OTHER INFORMATION  
   
Item 1. Legal Proceedings 24
   
Item 1A. Risk Factors 24
   
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25
   
Item 3. Defaults Upon Senior Securities 25
   
Item 4. Mine Safety Disclosure 25
   
Item 5. Other Information 25
   
Item 6. Exhibits 26
   
Signatures 27

 

 

2 
 

 

 

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

BALANCE SHEETS

(Unaudited)

 

           
   September 30, 2023   December 31, 2022 
ASSETS          
Current Assets          
Cash  $12,396   $25,550 
Prepaid expenses (Note 3)   1,050    1,050 
Total current assets   13,446    26,600 
           
Intangible assets (Note 4)   437,449    436,270 
           
Total assets  $450,895   $462,870 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current Liabilities          
Accounts payable and accrued liabilities  $12,562   $41,530 
           
Total liabilities   12,562    41,530 
Stockholders’ Equity          
Common stock, $0.0000053 par value; 500,000,000 common shares authorized; 338,880,151 and 322,880,151 shares issued and outstanding as at September 30, 2023 and December 31, 2022 respectively (Note 7)   1,811    1,726 
Additional paid-in capital   48,188,008    47,868,093 
Accumulated deficit   (47,751,486)   (47,448,479)
Total stockholders’ equity   438,333    421,340 
Total liabilities and stockholders’ equity  $450,895   $462,870 
           

 

Basis of Presentation – Going Concern Uncertainties (Note 1)

Commitments and Contingency (Note 9)

   

See Notes to Financial Statements

 

 

3 
 

 

 

 PROTOKINETIX, INCORPORATED

(A Development Stage Company)

STATEMENTS OF OPERATIONS

(Unaudited)

For the Three and Nine Months Ended September 30, 2023 and 2022

  

                     
   Three months ended
September 30, 2023
   Three months ended
September 30, 2022
   Nine months ended
September 30, 2023
   Nine months ended
September 30, 2022
 
EXPENSES                    
Amortization – intangible assets (Note 4)  $11,187   $750   $33,452   $2,250 
General and administrative   16,539    31,690    85,018    146,227 
Professional fees   31,370    33,122    108,581    121,015 
Research and development   21,295    160,994    75,956    426,968 
Share-based compensation (Notes 5 and 8)         143,486          627,192 
                     
Operating Income (Expenses)   (80,391)   (370,042)   (303,007)   (1,323,652)
                     
Net loss for the period  $(80,391)  $(370,042)  $(303,007)  $(1,323,652)
Net loss per common share (basic and diluted)  $(0.01)  $(0.00)  $(0.01)  $(0.01)
                     
Weighted average number of common shares outstanding (basic and diluted)   335,630,151    290,989,603    331,075,206    299,244,493 

  

 

See Notes to Financial Statements

 

4 
 

 

PROTOKINETIX, INCORPORATED

STATEMENT OF STOCKHOLDERS’ EQUITY

(Unaudited)

 

For the Nine Months Ended September 30, 2023 

 

                          
   Common Stock   Additional
Paid-in
   Accumulated     
   Shares   Amount   capital   deficit   Total 
Balance, December 31, 2022   322,880,151   $1,726   $47,868,093   $(47,448,479)  $421,340 
                          
Issuance of common stock pursuant to private placement offering   16,000,000    85    319,915          320,000 
                          
Net loss for the period   —                  (303,007)   (303,007)
                          
Balance, September 30, 2023   338,880,151   $1,811   $48,188,008   $(47,751,486)  $438,333 

 

 

For the Three Months Ended September 30, 2023

 

                 
   Common Stock   Additional
Paid-in
   Accumulated     
   Shares   Amount   capital   deficit   Total 
Balance, June 30, 2023   335,630,151   $1,795   $48,123,024   $(47,671,094)  $453,725 
                          
Issuance of common stock pursuant to private placement offering   3,250,000    16    64,984          65,000 
                          
Net loss for the period   —                  (80,392)   (80,392)
                          
Balance, September 30, 2023   338,880,151   $1,811   $48,188,008   $(47,751,486)  $438,333 

 

 

For the Nine Months Ended September 30, 2022

 

   Common Stock   Additional
Paid-in
   Accumulated     
   Shares   Amount   capital   deficit   Total 
Balance, December 31, 2021   297,393,485   $1,591   $45,892,545   $(45,541,170)  $352,966 
                          
Issuance of common stock pursuant to private placement offering   16,936,666    90    718,110          718,200 
                          
Fair value of share-based compensation   —            627,192          627,192 
                          
Net loss for the period   —                  (1,323,652)   (1,323,652)
                          
Balance, September 30, 2022   314,330,151   $1,681   $47,237,847   $(46,864,822)  $374,706 

   

 

For the Three Months Ended September 30, 2022

    

   Common Stock   Additional
Paid-in
   Accumulated     
   Shares   Amount   capital   deficit   Total 
Balance, June 30, 2022   306,830,151   $1,641   $46,869,401   $(46,494,780)  $376,262 
                          
Issuance of common stock pursuant to private placement offering   7,500,000    40    224,960          225,000 
                          
Fair value of share-based compensation   —            143,486          143,486 
                          
Net loss for the period   —                  (370,042)   (370,042)
                          
Balance, September 30, 2022   314,330,151   $1,681   $47,237,847   $(46,864,822)  $374,706 

 

See Notes to Financial Statements

 

 

5 
 

 

   

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

STATEMENTS OF CASH FLOWS

(Unaudited)

 For the Nine Months Ended September 30, 2023 and 2022

 

           
   Nine Months
ended
September 30, 2023
   Nine Months
ended
September 30, 2022
 
         
CASH FLOWS USED IN OPERATING ACTIVITIES          
Net loss for the period  $(303,007)  $(1,323,652)
Adjustments to reconcile net loss to cash used in operating activities:          
Amortization – intangible assets   33,452    2,250 
Fair value of share-based compensation         627,192 
Changes in operating assets and liabilities:          
Prepaid expenses         24,945 
Accounts payable and accrued liabilities   (28,968)   11,765 
           
Net cash used in operating activities   (298,523)   (657,500)
           
CASH FLOWS USED IN INVESTING ACTIVITIES          
Purchase of intangible assets   (34,631)   (74,556)
           
Net cash used in investing activities   (34,631)   (74,556)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Issuance of common stock for cash   320,000    718,200 
           
Net cash from financing activities   320,000    718,200 
           
Net change in cash   (13,154)   (13,856)
           
Cash, beginning of period   25,550    57,568 
           
Cash, end of period  $12,396   $43,712 
           
Cash paid for interest  $     $   
           
Cash paid for income taxes  $     $   

 

See Notes to Financial Statements

 

 

6 
 

 

 

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

September 30, 2023

 

Note 1.  Basis of Presentation – Going Concern Uncertainties

 

ProtoKinetix, Incorporated (the “Company”), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999.  The Company is a medical research company whose mission is the advancement of human health care.

 

The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins (“AFGP”) or anti-aging glycoproteins, trademarked AAGP.  During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $30,000 (25,000 Euros), as well as additional patent applications for cash consideration of $10,000 and 6,000,000 share purchase warrants with a fair value of $25,000 (Note 4).

 

The Company’s financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.

 

The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at September 30,2023.  These factors raise substantial doubt about the Company’s ability to continue as a going concern.

 

The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities.  Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective.  Management is presently engaged in seeking additional working capital through equity financing or related party loans. In addition, any significant disruption of global financial markets, reducing our ability to access capital, could negatively affect our liquidity and ability to continue operations. The exact impact is and will remain unknown and largely dependent upon future developments, including but not limited to changes in customer demand, additional mitigation strategies proposed by governmental authorities (including federal, state, or local stay at home or similar orders), restrictions on the activities of our domestic and international suppliers and shipment of goods.

 

The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

Note 2. Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K, filed March 17, 2023, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.

 

 

7 

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

September 30, 2023

 

 

  

 

Note 2. Summary of Significant Accounting Policies (cont’d)

 

Use of Estimates

 

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates as to valuation of equity related instruments issued, deferred income taxes, and the useful life and impairment of intangible assets.

 

Cash

 

Cash consists of funds held in checking accounts.  Cash balances may exceed federally insured limits from time to time.

 

Fair Value of Financial Instruments

 

Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.

 

The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:

 

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

 

Level 1 inputs are used to measure cash. At September 30, 2023, there were no other assets or liabilities subject to additional disclosure.

 

Income Taxes

 

The Company accounts for income taxes following the asset and liability method in accordance with the ASC 740 “Income Taxes.”  Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  The Company applies the accounting guidance issued to address the accounting for uncertain tax positions.  This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.

 

8 

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

September 30, 2023

 

 

 

Note 2. Summary of Significant Accounting Policies (cont’d)

 

Intangible assets – patent and patent application costs

 

The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.

 

As at September 30, 2023, the Company does not hold any intangible assets with indefinite lives.

 

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.

 

Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents. No amortization is recognized on patent application costs, as amortization of these costs will only commence once the patents have been granted.

 

Research and Development Costs

 

Research and development costs are expensed as incurred.

 

Loss per Share and Potentially Dilutive Securities

 

Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period.  Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities.  The effect of 94,290,000 stock options (September 30, 2022 – 94,690,000), and 13,300,000 warrants (September 30, 2022 – 14,800,000) were not included in the computation of diluted loss per share at September 30, 2023 for all periods presented because it was anti-dilutive at September 30, 2023 due to the Company’s losses.

 

Share-Based Compensation

 

The Company has granted warrants and options to purchase shares of the Company’s common stock to various parties for consulting services.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

 

The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance.

 

 

9 

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

September 30, 2023

 

 

 

 

Note 2. Summary of Significant Accounting Policies (cont’d)

 

Share-Based Compensation (cont’d)

 

Share-based compensation for non-employees in exchange for goods and services used or consumed in an entity’s own operations are also recorded at fair value on the measurement date and accounted for in accordance with ASC 718. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

 

Common stock

 

Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty’s performance is complete.

 

Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.

 

Related Party Transactions

 

A related party is generally defined as (i) any person that holds 10% or more of the Company’s securities and their immediate families, (ii) the Company’s management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company.  A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

 

Recent Accounting Pronouncements

 

Certain new accounting pronouncements that have been issued are not expected to have a material effect on the Company’s financial statements.

 

10 

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

September 30, 2023

 

 

  

Note 3.   Prepaid Expenses

 

The following summarizes the Company’s prepaid expenses outstanding as at September 30, 2023 and December 31, 2022:

 

          
   September 30,
 2023
   December 31,
  2022
 
Rental deposit  $1,050   $1,050 
           

  

 

11 

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

September 30, 2023

 

 

 

Note 4.   Intangible Assets

 

Intangible asset transactions are summarized as follows:

 

               
   Patent Rights   Patent Application
Rights
   Total 
Cost               
Balance, December 31, 2021  $30,000   $352,171   $382,171 
Additions         132,049    132,049 
Balance, December 31, 2022  $30,000   $484,220   $514,220 
Additions         34,631    34,631 
Balance, September 30, 2023  $30,000   $518,851   $548,851 
Accumulated amortization               
Balance, December 31, 2021  $19,500   $     $19,500 
Amortization   3,000    55,450    58,450 
Balance, December 31, 2022  $22,500   $55,450   $77,950 
Amortization   2,250    31,202    33,452 
Balance, September 30, 2023  $24,750    86,652   $111,402 
                
Net carrying amounts               
December 31, 2022  $7,500   $428,770   $436,270 
Balance, September 30, 2023  $5,250   $432,199   $437,449 

 

During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the "Patent Assignment") with the Institut National des Sciences Appliquees de Rouen ("INSA") for the assignment of certain patents and all rights associated therewith (the "Patents"). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $30,000 (25,000 Euros) (paid). During the nine month period September 30, 2023, the Company recorded $33,452 (2022 - $2,250) in amortization expense associated with the Patents Rights.

 

During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the "Patent Application Rights").  In exchange for the Patent Application Rights, the Company agreed to pay $10,000 (paid) and to issue 6,000,000 warrants (issued) to purchase shares of the Company's common stock at an exercise price of $0.10 per share for a period of five years. The Patent Application Rights had a total fair value of $35,000, which was allocated as $10,000 to the cash consideration paid, with the remaining $25,000 being allocated to the warrant component of the overall consideration. The Company incurred an additional $518,851 in direct costs relating to the Patent Application Rights, $34,631 of which were incurred during nine month period ended September 30, 2023.

 

 

12 

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

September 30, 2023

 

 

Note 4.  Intangible Assets (cont’d)

 

The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty from any product developed as a result of research done at the University.

 

During the year ended December 31, 2016, the Company entered into a Universal Assignment with Grant Young for the assignment of his ownership of certain new and useful improvements in an invention entitled “Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells” (the “New Patent Application Rights”).  In exchange for the New Patent Application Rights, the Company agreed to pay $1 (paid).  The Company incurred $2,415 in direct costs relating to the New Patent Application Rights during the year ended December 31, 2016.

 

The Company amortizes patents and licenses that have been filed over their useful lives which range between 18.5 to 20 years. The costs of provisional patents and pending applications is not amortized until the patent is filed and is reviewed each reporting period. No amortization was recorded on the Patent Application Rights or the New Patent Application Rights to September 30, 2023.

  

Note 5.  Stock Options

 

Pursuant to an amendment on March 15, 2022, the aggregate number of shares that may be issued under the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”) is 97,700,000 shares, subject to adjustment as provided therein. The 2017 Plan is administered by the Company’s Board of Directors, or a committee appointed by the Board of Directors, and includes two types of options. Options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended, are referred to as incentive options. Options that are not intended to qualify as incentive options are referred to as non-qualified options. The exercise price of an option may be paid in cash, in shares of the Company's common stock or other property having a fair market value equal to the exercise price of the option, or in a combination of cash, shares, other securities and property.

 

As of September 30, 2023, there are 94,290,000 options granted and outstanding under the 2017 Plan.

 

13 

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

September 30, 2023

 

 

 

Note 5.  Stock Options (cont’d)

 

Total share-based compensation for stock options granted during the nine-month period ended September 30, 2023 was $Nil (2022 - $627,192)

Stock option transactions are summarized as follows: 

 

               
   Number of
Stock Options
   Weighted Average Exercise Price   Weighted Average Remaining Life 
       $   (Years) 
Outstanding, December 31, 2021   84,690,000    0.15      
     Options cancelled   (93,540,000)   0.14      
     Options exercised   (400,000)   0.06      
     Options granted   103,540,000    0.03      
Outstanding, December 31, 2022   94,290,000    0.03    6.00 

 

             
   Number of
Stock Options
   Weighted Average Exercise Price   Weighted Average Remaining Life 
       $   (Years) 
Outstanding, December 31, 2022   94,290,000    0.03      
   Options cancelled             
   Options granted             
Outstanding, September 30, 2023   94,290,000    0.03    5.00 

   

The following non-qualified stock options were outstanding and exercisable at September 30, 2023:

 

            
Expiry date  Exercise Price   Number of Options
Outstanding
   Number of
Options
Exercisable
 
   $         
 October 25, 2026   0.10    500,000    500,000 
 November 26, 2026   0.10    250,000    250,000 
 December 6, 2028   0.028    93,540,000    93,540,000 
         94,290,000    94,290,000 

 

As at September 30, 2023, the aggregate intrinsic value of the Company’s stock options is $ Nil (September 30, 2022 – $Nil ). The weighted average fair value of stock options granted during the nine-month period ended September 30, 2023 is $Nil (2022 - $Nil ).

 

 

14 

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

September 30, 2023

 

 

 

Note 6.  Warrants

 

Warrant transactions for the nine-months ended September 30, 2023 are summarized as follows:

 

        
   Number of
Warrants
   Weighted Average Exercise Price 
       $ 
Outstanding, December 31, 2021   12,081,143    0.17 
   Warrants granted   13,300,000    0.04 
   Warrants expired   (6,081,143)   0.09 
   Warrants cancelled   (6,000,000)   0.26 
Outstanding, December 31, 2022 and September 30, 2023   13,300,000    0.04 

  

The following warrants were outstanding and exercisable as at September 30, 2023:

 

           
Number of Warrants     Exercise Price     Expiry Date
  1,000,000     $ 0.05     March 15, 2024
  200,000       0.05     March 15, 2024
  1,000,000       0.05     March 15, 2024
  600,000       0.05     March 15, 2024
  1,000,000       0.05     March 15, 2024
  500,000       0.05     March 15, 2024
  1,000,000       0.05     March 15, 2024
  2,000,000       0.05     March 15, 2024
  6,000,000       0.028     December 12, 2028
  13,300,000              

 

 

 

15 

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

September 30, 2023

 

 

 

Note 7.  Stockholders’ Equity

 

The Company is authorized to issue 500,000,000 (December 31, 2022 – 500,000,000) shares of $0.0000053 par value common stock. Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of September 30, 2023 (September 30, 2022 - $ nil).

 

During the nine-month period ended September 30, 2023, the Company:

 

  a) Issued 16,000,000 shares of common stock (16,000,000 shares issued at $0.02) as part of a private placement for total proceeds of $320,000.

  

During the nine-month period ended September 30, 2022, the Company:

 

  a) Issued 7,500,000 shares of common stock (7,500,000 shares issued at $0.03) as part of a private placement for total proceeds of $225,000.

  

  b) Issued 2,136,666 shares  of common stock (2,136,666 shares issued at $0.06) as part of a private placement for total proceeds of $128,200.

  

  c) Issued 7,300,000 units (each unit consisting of one share of common stock and one warrant to purchase one share of common stock $0.05) as part of a private placement for total proceeds of $365,000.

  

Note 8. Related Party Transactions and Balances

 

During the nine-month periods ended September 30, 2023 and 2022, the Company entered into the following related party transactions:

a) Pursuant to a consulting agreement with an effective date of November 14, 2017, a total of $45,000 (September 30, 2022 - $45,000) was paid or accrued to the Company's CFO. During the nine months ended September 30, 2023, the Company reimbursed a company controlled by the CFO a total of $4,500 (September 30, 2022 - $9,450) in office rent.

b) On March 15, 2022, the Company granted 4,750,000 stock options to the Company’s CEO and 500,000 stock options to a Director of the Company, respectively. The 5,250,000 options granted have a term of 8 years and are exercisable at a price of $0.06 per share, expiring on March 14, 2030. The options were cancelled and replaced on December 7, 2022 with options exercisable at $0.028 per share and expiring on December 6, 2028.

c) On March 15, 2022, the Company granted 1,500,000 stock options to the Company’s CFO. The options granted have a term of 8 years and are exercisable at a price of $0.06 per share, expiring on March 14, 2030. The options were cancelled and replaced on December 7, 2022 with options exercisable at $0.028 per share and expiring on December 6, 2028.

d) The Company recognized $nil (2022 - $338,348) in share-based compensation during the period associated with stock options granted to key management personnel

As at September 30, 2023 and September 30, 2022, there were $nil balances owing to related parties.

 

16 

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

 

NOTES TO FINANCIAL STATEMENTS

September 30, 2023

 

 

  

 

Note 9.  Commitments and Contingency

 

As at September 30, 2023, the Company has the following commitments:

 

a) Entered into a consulting agreement with an effective date of January 1, 2017 whereby the Company would pay the consultant $7,000 per month for providing research and development services.

b) Entered into a consulting agreement effective April 1, 2019, whereby the Company would pay the consultant $1,500 per month minimum plus travel expenses for providing research consulting services. The agreement renews annually unless otherwise terminated by either party with at least 30 days’ notice. The agreement is in effect as of September 30, 2023.

 

17 
 

 

 

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Unless the context requires otherwise, references in this document to “ProtoKinetix”, “we”, “our”, “us” or the “Company” are to ProtoKinetix, Incorporated.

 

The following discussion provides information regarding the results of operations for the nine-month period ended September 30, 2023 and 2022, and our financial condition, liquidity and capital resources as of September 30, 2023 and December 31, 2022.  The financial statements and the notes thereto contain detailed information that should be referred to in conjunction with this discussion.

 

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”).  All statements, other than statements of historical facts, included herein and therein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward-looking statements. These forward-looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,” “will,” “continue,” “potential,” “should,” “could,” and similar terms and phrases.  Although we believe that the expectations reflected in these forward-looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not considered to be) guarantees of future performance. Our results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, among others:

 

  Our capital requirements and the uncertainty of being able to obtain additional funding on terms acceptable to us;

 

  Our plans to develop and commercialize products from the AAGP® molecule;

 

  Ongoing testing of the AAGP® molecule;

 

  Our intellectual property position;

 

  Our commercialization, marketing and manufacturing capabilities and strategy;

 

  Our ability to retain key members of our senior management and key scientific consultants;

 

 

18 
 

 

 

 

  The effects of competition;

 

  Our potential tax liabilities resulting from conducting business in the United States and Canada;

 

  The effect of further sales or issuances of our common stock and the price and volume volatility of our common stock; and

 

  Our common stock’s limited trading history.

 

Finally, our future results will depend upon various other risks and uncertainties, including, but not limited to, those detailed in our filings with the SEC under the Exchange Act and the Securities Act, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and our Quarterly Report on Form 10-Q for the period ended September 30, 2023.  All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this paragraph and elsewhere in this Quarterly Report. Other than as required under securities laws, we do not assume a duty to update these forward-looking statements, whether as a result of new information, subsequent events or circumstances, changes in expectations or otherwise.

 

Business Overview

 

ProtoKinetix, Incorporated is a research and development stage bio-technology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins) or anti-aging glycoproteins, trademarked as AAGP®.  The Company has recently been in the process of directing major efforts to the practical side of commercial validation.  The commercial applications for AAGP® in large markets such as targeted health care solutions are numerous, and ProtoKinetix is currently working with researchers, business leaders and advisors and commercial entities to bring AAGP® to market.

 

In March 2020, the World Health Organization declared coronavirus Covid-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn.

 

As of the date of this filing, the Company has regained a significant portion of its operational capacity and we continue to move forward with our research goals. Our supply of the patented AAGP® molecule has been manufactured and stored in the United States and we have adequate inventory to carry out the projects currently underway. The Company engages contract research organizations (CROs) located in both the United States and Canada. The CROs contracted by the Company for research projects have been able to meet milestone goals without disruption due to the pandemic. In January of 2020, Protokinetix signed a master supply agreement with University of Alberta that clears the way for testing of additional patients in the Phase I clinical trials.  The global pandemic halted all work on clinical trials and research testing for most of 2020. Phase I trials were able restart mid-year 2021 but new strains of Covid continue to plague the US and Canada. We cannot accurately predict a completion date of Phase I trials.

We continue to monitor the status of the pandemic and will adjust our strategy accordingly in order to mitigate the impact on our research projects. The Company survived the adverse effects of the 2020 Covid outbreak and as at September 30, 2023 continues to carry out operations including raising funds for ongoing research and product development.

19 
 

 

 

Results of Operations

 The following table shows selected financial data and operating results for the periods noted.  Following the table, please see management’s discussion of significant changes.

 

   For the Nine Months Ended 
   September 30, 
   2023   2022 
EXPENSES        
Amortization  $33,452   $2,250 
General and Administrative   85,018    146,227 
Professional Fees   108,581    121,015 
Research and Development   75,956    426,968 
Share-Based Compensation   —      627,192 
Net loss for the period  $(303,007)  $(1,323,652)

  

Gross Profit and Expenses

The Company’s net loss was $303,006 for the nine-month period ended September 30, 2023 compared to $1,323,652 for the nine-month period ended September 30, 2022.  The expenses were primarily incurred for professional fees, consulting services related to the operations of the Company’s business, research and development and other general and administrative expenses.  Significant changes from the prior nine-month period ended September 30, 2022 include:

 

General and administrative fees dropped by $61,209 from $146,227 to $85,018 primarily as a result of a decrease in spending on social media advertising, and investor relations. Additionally, there are no current year project expenses related to product development and marketing expenses have been significantly reduced.

 

Professional fees decreased by $10,681 from $121,015 to $108,581 due to decreases in legal and filing fees associated with private placement offering and SEC reporting, as well as the reduction in use of outside consultants.

 

Research and development expenditures remain lower year over year with a change of $351,012 from $426,968 to $75,956 as the Company pursues research partners for cost sharing and engages institutes with grants available for continued studies on our patented AAGP molecule.

 

Share-based compensation decreased by $627,192 from $627,192 to $Nil as a result of no further stock options being granted to directors and management of the Company as at September 30,2023.

 

 

20 
 

 

 

 

Liquidity and Capital Resources

The following summarizes our balance sheet at September 30, 2023 and December 31, 2022:

 

   September 30, 2023   December 31, 2022 
Cash  $12,396   $25,550 
           
Working Capital  (deficiency)  $884   $(14,930)

 

 At September 30, 2023, we had $12,396 in cash and $13,446 in total current assets and a working capital equity position of $884. Based upon our working capital equity as of September 30, 2023, we will require additional equity and/or debt financing in order to meet cash flow projections and carry forward our business objectives.  

 

There can be no assurance that in the future we will be able to raise capital from outside sources in sufficient amounts to fund our new business. The failure to secure adequate outside funding would have an adverse effect on our plan of operation and results therefrom and a corresponding negative impact on stockholder liquidity.

 

Sources and Uses of Cash

 

Net Cash Used in Operating Activities

 

Net cash used in operating activities fell by $358,977 from $657,500 to $298,523 for the nine-months ended September 30, 2022, and 2023, respectively. With the year over year change due to a reduction in accounts payable and significantly less research and development for nine-month period ended September 30, 2023.

 

Net Cash Used in Investing Activities

 

Net cash used in investing activities was $34,631 for the nine-month period ended September 30, 2023 while the Company had net cash used in investing activities of $74,556 for the comparative period.  Minimal change year-over-year to scheduled maintenance fees on existing international patent portfolio with mid-year fees larger in prior year for the same period.

 

Net Cash Provided by Financing Activities

 

Net cash provided by financing activities decreased $238,200 from $718,200 to $320,000 for the nine-months ended September 30, 2022, and 2023, respectively. The decrease of funding from private placements through the first nine months of 2023 reflects the focus on finding financial partners for further research and development. Private placement investment has been narrowed to updates and expansions of existing studies.

 

Going Concern

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”), which contemplate continuation of the Company as a going concern.  The history of losses and the inability for the Company to make a profit from selling a good or service has raised substantial doubt about our ability to continue as a going concern. In spite of the fact that the current cash obligations of the Company are relatively minimal, given the cash position of the Company, we have very little cash to operate. We intend to fund the Company and attempt to meet corporate obligations by selling common stock.  However, the price and volume of the Company’s common stock is volatile.

 

Off-Balance Sheet Arrangements

 

None.

 

Contractual Obligations

 

As a smaller reporting company, we are not required to provide the information required by paragraph (a)(5) of this Item.

 

 

21 
 

 

 

Critical Accounting Policies

The preparation of financial statements in conformity with U.S. GAAP requires management to make a variety of estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and (ii) the reported amounts of revenues and expenses during the reporting periods covered by the financial statements. 

 

Our management routinely makes judgments and estimates about the effect of matters that are inherently uncertain. As the number of variables and assumptions affecting the future resolution of the uncertainties increase, these judgments become even more subjective and complex. Although we believe that our estimates and assumptions are reasonable, actual results may differ significantly from these estimates. Changes in estimates and assumptions based upon actual results may have a material impact on our results of operation and/or financial condition. Our significant accounting policies are disclosed in Note 2 to the Financial Statements included in this Form 10-Q.

 

While all of the significant accounting policies are important to the Company’s financial statements, the following accounting policies and the estimates derived there from have been identified as being critical.

 

Share-Based Compensation

 

The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance.

 

Share-Based Compensation for non-employees in exchange for goods and services used or consumed in an entity’s own operations are also recorded at fair value on the measurement date and accounted for in accordance with ASC 718. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

 

Sales and Marketing

 

The Company is currently not selling or marketing any products.

 

Inflation

 

Although management expects that our operations will be influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the nine months ended September 30, 2023.

 

 

22 
 

 

 

Item 3. Quantitative and Qualitative Disclosure About Market Risk

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

 

Item 4: Controls and Procedures

 

Disclosure Controls and Procedures

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 (the “1934 Act”) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the 1934 Act is accumulated and communicated to management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Our management, under the direction of our Chief Executive Officer (who is our principal executive officer), and Chief Financial Officer (who is our principal accounting officer) has evaluated the effectiveness of our disclosure controls and procedures as required by 1934 Act Rule 13a-15(b) as of September 30, 2023 (the end of the period covered by this report).  Based on that evaluation, our principal executive officer and our principal accounting officer concluded that these disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosure and are effective to provide reasonable assurance that such information is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

 

The Company, including its Chief Executive Officer and Chief Financial Officer, does not expect that its internal controls and procedures will prevent or detect all error and all fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

 

Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) promulgated by the SEC under the 1934 Act) during the nine-months ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

23 
 

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

Other than previously reported, the Company and its management are not aware of any regulatory or legal proceedings or investigations pending involving the Company, any of its subsidiaries or affiliates, or any of their respective officers, directors or employees.

 

Item 1A. Risk Factors

 

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.  However, our current risk factors are set forth in our Annual Report on Form 10-K for the year ended December 31, 2022 as filed with the SEC on March 17, 2023 and our Quarterly Report on Form 10-Q for the period ended June 30, 2023 as filed with the SEC on July 14, 2023.

 

War in the Ukraine may impact the business of the Company and the financial markets in which the Company needs to raise capital.

 

Political and military events in Ukraine, including the 2022 Russian invasion of Ukraine, as well as ongoing tensions and intermittent warfare between Ukraine may have an adverse impact on our ability to grow our business.

  

For so long as the hostilities continue and perhaps even thereafter as the situation in Europe unfolds, we may see increased volatility in financial markets and a flight to safety by investors, which may make it more difficult for the Company to raise additional capital at the time when it needs to do so, or for financing to be available upon acceptable terms. We cannot predict the timing, strength, or duration of any economic slowdown, instability or recovery.

 

Moreover, retaliatory acts by Russia in response to economic sanctions or other measures taken by the international community could include an increased number or severity of cyber-attacks from Russia or its allies. We are dependent on information technology systems, and any interruption, breach, or security lapse of those systems could adversely affect our results of operations. For example, the loss of data from any clinical trials could result in delays in research and development, and the loss, corruption, or unauthorized disclosure of our trade secrets, patents, or other proprietary information could compromise the commercial viability of our products. We may also incur additional costs in the future related to the implementation of additional security measures to protect against new or enhanced data security and privacy threats, or to comply with state, federal and international laws that may be enacted to address those threats.

 

All or any of these risks separately, or in combination could have a material adverse effect on our business, financial condition, results of operations, and cash flows.

 

We may be adversely affected by the effects of inflation.

Inflation has the potential to adversely affect our liquidity, business, financial condition and results of operations by increasing our overall cost structure. The existence of inflation in the economy has resulted in, and may continue to result in, higher interest rates and capital costs, supply shortages, increased costs of labor, components, manufacturing and shipping, as well as weakening exchange rates and other similar effects. As a result of inflation, we have experienced and may continue to experience cost increases. Although we may take measures to mitigate the effects of inflation, if these measures are not effective, our business, financial condition, results of operations and liquidity could be materially adversely affected. Even if such measures are effective, there could be a difference between the timing of when these beneficial actions impact our results of operations and when the cost of inflation is incurred. 

 

24 
 

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Between July 31, 2023 and August 30, 2023, the Company issued 3,250,000 shares of common stock to accredited investors in a private placement for gross proceeds of $65,000, of which, the Company’s President and CEO, Clarence E. Smith, purchased 1,500,000 shares. Each share of common stock had a purchase price of $0.02 per share. No solicitation was used in the offering. The Company relied on the exemption from registration available under Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”) and/or Rule 506(b) of Regulation D promulgated under the 1933 Act with respect to transactions by an issuer not involving any public offering.  No commissions were paid in connection with these issuances of securities. The Company filed a Form D with the SEC on January 6, 2023, as amended on February 7, 2023, May 25, 2023, and June 16, 2023 and September 7, 2023.

 

Item 3. Defaults upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosure

 

Not applicable.

 

Item 5. Other Information

 

None.

 

 

25 
 

 

 

   

 

Item 6. Exhibits

 

The following is a complete list of exhibits filed as part of this Form 10-Q.  Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-K.

 

EXHIBIT INDEX

 

The following documents are being filed with the Commission as exhibits to this Quarterly Report on Form 10-Q.

 

Exhibit   Description
3.1   Amended and Restated Articles of Incorporation as filed on February 16, 2022(1)
3.2   Amended and Restated Bylaws of the Company as approved on December 20, 2021(2)
4.1   Amended 2017 Stock Option and Stock Bonus Plan(3)
4.2   Amendment to Amended 2017 Stock Option and Stock Bonus Plan as approved on July 15, 2019(6)
4.3   Amendment to Amended 2017 Stock Option and Stock Bonus Plan as approved on April 6, 2020(10)
4.4   Amendment to Amended 2017 Stock Option and Stock Bonus Plan as approved on March 15, 2022(12)
10.1   Royalty Agreement between the Company and The Governors of the University of Alberta, dated April 8, 2015(4)
10.2   Collaborative Research Agreement between the Company and the University of British Columbia, dated May 31, 2016(5)
10.3   Consulting Agreement between the Company and Clarence E. Smith, dated December 30, 2016(7)
10.4   Director Consulting Agreement between the Company and Edward P. McDonough, dated December 30, 2016(7)
10.5   Consulting Agreement between the Company and Grant Young, dated December 30, 2016(8)
10.6   First Amendment to Consulting Agreement between Clarence E. Smith and the Company dated September 1, 2017(9)
10.7   First Amendment to Consulting Agreement between Grant Young and the Company dated September 1, 2017(9)
10.8   First Amendment to Consulting Agreement between Edward P. McDonough and the Company dated September 1, 2017(9)
10.9   Consulting Agreement between ProtoKinetix Incorporated and Michael Guzzetta, dated November 14, 2017(11)
31.1   Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
31.2   Certification of the Principal Financial Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32   Certification of the Principal Executive Officer and the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
101.INS   XBRL Instance Document
101.SCH   XBRL Schema Document 
101.CAL   XBRL Calculation Linkbase Document 
101.DEF   XBRL Definition Linkbase Document 
101.LAB   XBRL Label Linkbase Document
101.PRE   XBRL Presentation Linkbase Document  
104   Cover Page Interactive Date File (formatted in Incline XBRL and contained in Exhibit 101)*

 

  1. Incorporated by reference from the Company’s Current Report on Form 8-K filed on February 14, 2022 with the SEC.

  2. Incorporated by reference from the Company’s Current Report on Form 8-K filed on December 23, 2021 with the SEC.

  3. Incorporated by reference from the Company’s Current Report on Form 8-K filed on November 13, 2018 with the SEC.

  4. Incorporated by reference from the Company’s Annual Report on Form 10-K filed on April 14, 2015 with the SEC.

  5. Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on August 15, 2016 with the SEC.

  6. Incorporated by reference from the Company’s Current Report on Form 8-K filed on July 17, 2019 with the SEC.

  7. Incorporated by reference from the Company’s Annual Report on Form 10-K filed on February 21, 2017 with the SEC.

  8. Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on November 13, 2017 with the SEC.

  9. Incorporated by reference from the Company’s amended Current Report on Form 8-K filed on September 12, 2017 with the SEC.

  10. Incorporated by reference from the Company’s Current Report on Form 8-K filed on April 10, 2020 with the SEC.
  11. Incorporated by reference from the Company’s Current Report on Form 8-K filed on November 15, 2017 with the SEC.
  12. Incorporated by reference from the Company’s Current Report on Form 8-K filed on March 21, 2022 with the SEC.

 

  * Filed herewith.

 

  ** Furnished, not filed herewith.

 

26 
 

 

 

 SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: October 18, 2023   PROTOKINETIX, INCORPORATED
     
    By: /s/ Clarence E. Smith
    Clarence E. Smith
    Chief Executive Officer
     
    By: /s/ Michael Guzzetta
    Michael Guzzetta
    Chief Financial Officer

 

 

 

 

 

27